These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2645 related articles for article (PubMed ID: 20087739)

  • 21. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care.
    Brufsky A
    Am J Clin Oncol; 2010 Apr; 33(2):186-95. PubMed ID: 19675448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
    Cameron DA; Stein S
    Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.
    Perez EA; Patel T; Moreno-Aspitia A
    Breast Cancer Res Treat; 2010 Jun; 121(2):261-71. PubMed ID: 20229176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
    Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T
    Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells.
    Yang Z; Barnes CJ; Kumar R
    Clin Cancer Res; 2004 Jun; 10(11):3621-8. PubMed ID: 15173068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
    Damasceno M
    Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy.
    Montemurro F; Aglietta M
    Endocr Relat Cancer; 2009 Dec; 16(4):1091-102. PubMed ID: 19726539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.
    Marcom PK; Isaacs C; Harris L; Wong ZW; Kommarreddy A; Novielli N; Mann G; Tao Y; Ellis MJ
    Breast Cancer Res Treat; 2007 Mar; 102(1):43-9. PubMed ID: 16897431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
    Bianchini G; Iwamoto T; Qi Y; Coutant C; Shiang CY; Wang B; Santarpia L; Valero V; Hortobagyi GN; Symmans WF; Gianni L; Pusztai L
    Cancer Res; 2010 Nov; 70(21):8852-62. PubMed ID: 20959472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An overview of HER-targeted therapy with lapatinib in breast cancer.
    McArthur H
    Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments.
    Barros FF; Powe DG; Ellis IO; Green AR
    Histopathology; 2010 Apr; 56(5):560-72. PubMed ID: 20459566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Kemp Z; Jones A
    Adv Ther; 2011 Aug; 28(8):603-14. PubMed ID: 21833702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
    Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; dei Tos AP; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M
    Clin Breast Cancer; 2008 Oct; 8(5):436-42. PubMed ID: 18952558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New strategies in estrogen receptor-positive breast cancer.
    Johnston SR
    Clin Cancer Res; 2010 Apr; 16(7):1979-87. PubMed ID: 20332324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual HER2-targeted approaches in HER2-positive breast cancer.
    Ahn ER; Vogel CL
    Breast Cancer Res Treat; 2012 Jan; 131(2):371-83. PubMed ID: 21956210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
    de Ronde JJ; Hannemann J; Halfwerk H; Mulder L; Straver ME; Vrancken Peeters MJ; Wesseling J; van de Vijver M; Wessels LF; Rodenhuis S
    Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 133.